Medications

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Click a letter to see a list of medications beginning with that letter.

Serogroup B Meningococcal Vaccine (MenB)

Brand Name(s): Bexsero®, Trumenba®

Why get vaccinated?

Meningococcal B vaccine can help protect against meningococcal disease caused by serogroup B. A different meningococcal vaccine is available that can help protect against serogroups A, C, W, and Y.

Meningococcal disease can cause meningitis (infection of the lining of the brain and spinal cord) and infections of the blood. Even when it is treated, meningococcal disease kills 10 to 15 infected people out of 100. And of those who survive, about 10 to 20 out of every 100 will suffer disabilities such as hearing loss, brain damage, kidney damage, loss of limbs, nervous system problems, or severe scars from skin grafts.

Meningococcal disease is rare and has declined in the United States since the 1990s. However, it is a severe disease with a significant risk of death or lasting disabilities in people who get it.

Anyone can get meningococcal disease. Certain people are at increased risk, including:

Infants younger than one year old
Adolescents and young adults 16 through 23 years old
People with certain medical conditions that affect the immune system
Microbiologists who routinely work with isolates of N. meningitidis, the bacteria that cause meningococcal disease
People at risk because of an outbreak in their community

What are meningococcal group B vaccines?

For best protection, more than 1 dose of a meningococcal B vaccine is needed. There are two meningococcal B vaccines available. The same vaccine must be used for all doses.

Meningococcal B vaccines are recommended for people 10 years or older who are at increased risk for serogroup B meningococcal disease, including:

People at risk because of a serogroup B meningococcal disease outbreak
Anyone whose spleen is damaged or has been removed, including people with sickle cell disease
Anyone with a rare immune system condition called ''persistent complement component deficiency''
Anyone taking a type of drug called a "complement inhibitor," such as eculizumab (also called "Soliris"®) or ravulizumab (also called "Ultomiris"®)
Microbiologists who routinely work with isolates of N. meningitidis

These vaccines may also be given to anyone 16 through 23 years old to provide short-term protection against most strains of serogroup B meningococcal disease, based on discussions between the patient and health care provider. The preferred age for vaccination is 16 through 18 years.

Talk with your healthcare provider

Tell your vaccination provider if the person getting the vaccine:

Has had an allergic reaction after a previous dose of meningococcal B vaccine, or has any severe, life-threatening allergies
Is pregnant or breastfeeding.

In some cases, your health care provider may decide to postpone meningococcal B vaccination until a future visit.

Meningococcal B vaccination should be postponed for pregnant people unless the person is at increased risk and, after consultation with their health care provider, the benefits of vaccination are considered to outweigh the potential risks.

People with minor illnesses, such as a cold, may be vaccinated. People who are moderately or severely ill should usually wait until they recover before getting meningococcal B vaccine.

Your health care provider can give you more information.

What are the risks from meningococcal group B vaccines?

Soreness, redness, or swelling where the shot was given, tiredness, headache, muscle or joint pain, fever, or nausea can happen after meningococcal B vaccination. Some of these reactions occur in more than half of the people who receive the vaccine.

People sometimes faint after a medical procedure, including vaccination. Tell your doctor if you feel dizzy, or have vision changes or ringing in the ears.

As with any medicine, there is a very remote chance of a vaccine causing a serious injury or death.

What if there is a serious reaction?

An allergic reaction could occur after the vaccinated person leaves the clinic. If you see signs of a severe allergic reaction (hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, or weakness), call 9-1-1 and get the person to the nearest hospital.

For other signs that concern you, call your health care provider.

Adverse reactions should be reported to the Vaccine Adverse Event Reporting System (VAERS). Your health care provider will usually file this report, or you can do it yourself. Visit the VAERS website at http://www.vaers.hhs.gov or call 1-800-822-7967. VAERS is only for reporting reactions, and VAERS staff does not give medical advice.

The National Vaccine Injury Compensation Program

The National Vaccine Injury Compensation Program (VICP) is a federal program that was created to compensate people who may have been injured by certain vaccines. Claims regarding alleged injury or death due to vaccination have a time limit for filing, which may be as short as two years. Visit the VICP website at http://www.hrsa.gov/vaccinecompensation or call 1-800-338-2382 to learn about the program and about filing a claim.

How can I learn more?

Ask your health care provider. He or she can give you the vaccine package insert or suggest other sources of information.
Call your local or state health department.
Visit the website of the Food and Drug Administration (FDA) for vaccine package inserts and additional information at http://www.fda.gov/vaccines-blood-biologics/vaccines.
Contact the Centers for Disease Control and Prevention (CDC): Call 1-800-232-4636 (1-800-CDC-INFO) or visit CDC's website at http://www.cdc.gov/vaccines.

Serogroup B Meningococcal Vaccine Information Statement. U.S. Department of Health and Human Services/Centers for Disease Control and Prevention National Immunization Program. 8/6/2021.

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. represents that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. makes no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information is not a substitute for medical care.

Selected Revisions November 15, 2021, American Society of Health-System Pharmacists® 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814 USA. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.